세계의 동물용 의약품 시장은 2024년에 433억 달러에 달했고 2025년부터 2034년에 걸쳐 CAGR 6.1%를 나타낼 것으로 예측되고 있습니다.
시장 성장의 원동력이 되고 있는 것은 반려동물의 사육수 증가, 가축 헬스케어에 대한 수요 증가, 수의학의 진보입니다.
마찬가지로 축산업계에서는 질병의 예방과 생산성 향상이 중시되게 되어 특수한 의약품 수요가 높아지고 있습니다. 예방의료에 대한 의식의 고조는 혁신적인 동물용 의약품에 대한 규제 당국의 승인과 함께, 시장의 성장을 한층 더 가속시키고 있습니다.
| 시장 범위 | |
|---|---|
| 시작 연도 | 2024년 |
| 예측 연도 | 2025-2034년 |
| 시작 금액 | 433억 달러 |
| 예측 금액 | 789억 달러 |
| CAGR | 6.1% |
의약품의 기술 혁신과 유통망의 개선으로 동물용 의약품은 각 지역에서 입수하기 쉬워지고 있습니다. 반려동물 보험 가입이 급증하고 있기 때문에 주인은 고품질의 의약품에 투자하게 되어 치료의 연속성이 향상하고 있습니다.
2024년에는 감염증, 염증, 기생충증의 치료에 필수적인 역할을 하는 의약품 분야가 238억 달러로 시장을 선도했습니다. 제약회사는 최첨단 연구에 투자하고 있습니다. 반려동물의 주인은 동물의 건강에 대해 보다 적극적으로 되어, 회복이 빨리 장기적인 효과를 기대할 수 있는 처방약을 선택하게 되어 있습니다.
반려동물을 키우고 그 의료 케어를 우선하는 가정 증가를 반영하여 2024년 시장 점유율의 59.2%를 반려동물이 차지했습니다. 반려동물 보호자들이 동물의 수명과 삶의 질을 향상시키려는 노력으로 백신과 영양 보충제를 포함한 예방 치료에 대한 수요가 급증하고 있습니다.
북미는 2024년 시장 점유율의 41.4%를 차지했고 높은 반려동물 사육률과 확립된 수의 건강 관리 시스템에 의해 우위성을 유지하고 있습니다. 수의학적 치료에 대한 규제 당국의 지원이 높아지면서 업계의 성장을 뒷받침하고 있습니다.
The Global Animal Drugs Market reached USD 43.3 billion in 2024 and is projected to register a CAGR of 6.1% from 2025 to 2034. The market growth is driven by a combination of rising pet ownership, increasing demand for livestock healthcare, and advancements in veterinary medicine. As more people embrace pets as companions, the need for high-quality pharmaceuticals to address a wide range of health conditions is surging.
Likewise, the livestock industry is witnessing a growing emphasis on disease prevention and productivity enhancement, fueling demand for specialized drugs. The rising prevalence of chronic diseases in animals, including arthritis, diabetes, and cardiovascular disorders, is pushing veterinary expenditures higher, prompting the development of more effective treatment options. Increasing awareness about preventive care, coupled with regulatory approvals for innovative veterinary pharmaceuticals, is further accelerating market growth. With ongoing R&D efforts and improved accessibility to veterinary care, the industry is poised for continued expansion.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $43.3 Billion |
| Forecast Value | $78.9 Billion |
| CAGR | 6.1% |
Pharmaceutical innovations, in line with improved distribution networks, are making animal drugs more accessible across regions. Governments and private organizations are actively supporting veterinary research, leading to the introduction of advanced therapeutics designed to minimize recovery time and enhance overall animal well-being. Additionally, a surge in pet insurance coverage is encouraging pet owners to invest in high-quality medications, ensuring better treatment adherence.
The drugs segment led the market in 2024 with USD 23.8 billion, dominating due to its essential role in treating infections, inflammation, and parasitic infestations. Veterinary pharmaceuticals are increasingly being formulated to provide targeted treatment, reducing side effects and improving efficacy. The rising incidence of zoonotic diseases is also reinforcing the demand for advanced medications, prompting pharmaceutical companies to invest in cutting-edge research. Pet owners are becoming more proactive about their animals' health, opting for prescription medications that offer faster recovery and long-term benefits. Growing concerns over antimicrobial resistance are driving the adoption of alternative treatments, including probiotics and immunomodulators, further diversifying the drug landscape.
Companion animals accounted for 59.2% of the market share in 2024, reflecting the increasing number of households adopting pets and prioritizing their medical care. Rising disposable income, coupled with an emotional attachment to pets, is leading to higher veterinary spending, particularly on specialized medications. The demand for preventative treatments, including vaccines and nutritional supplements, is surging as pet owners seek to enhance their animals' longevity and quality of life. Technological advancements in veterinary diagnostics are also playing a key role in the segment's growth, enabling early disease detection and personalized treatment approaches.
North America accounted for 41.4% of the market share in 2024, maintaining its dominance due to high pet ownership rates and a well-established veterinary healthcare system. The region's significant livestock industry continues to drive demand for pharmaceuticals aimed at improving herd health and productivity. Expanding research initiatives, combined with growing regulatory support for innovative veterinary treatments, are reinforcing industry growth. The increasing availability of advanced treatment options, such as biologics and gene-based therapies, is shaping the future of animal healthcare, ensuring sustained demand for pharmaceuticals across the region.